Literature DB >> 23341375

Value of fluorescence cystoscopy in high risk non-muscle invasive bladder cancer.

Roman Mayr1, Maximilian Burger.   

Abstract

Photodynamic Diagnosis (PDD), an adjunct to white light cystoscopy, has been shown to improve detection and thoroughness of resection of bladder cancer by enhancing visualisation of malign lesions during transurethral resection of bladder tumours (TURBT) compared to the sole use of standard white light cystoscopy. The PDD also has been shown to improve recurrence of free survival in non-muscle invasive bladder cancer. Little data on its impact on outcome in non-muscle invasive bladder cancer of high risk of progression is available however. The few trials and studies available demonstrate improved accuracy of diagnosis especially of flat malign lesions. In addition, improved recurrence rates have been suggested without an impact on progression rates in early invasive bladder cancer indicating little influence of thoroughness of resection on the tumour biology in those tumour stages. While no specific and larger data on impact of PDD on cancer specific survival exist to date and the few long-term data suggest little impact, improved accuracy of diagnosis is suggested to be beneficial for clinical decision making and thus a value of PDD is postulated in the management of high-risk non-muscle invasive bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23341375     DOI: 10.1007/s11934-013-0306-0

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  22 in total

1.  Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies.

Authors:  D Zaak; M Kriegmair; H Stepp; H Stepp; R Baumgartner; R Oberneder; P Schneede; S Corvin; D Frimberger; R Knüchel; A Hofstetter
Journal:  Urology       Date:  2001-04       Impact factor: 2.649

2.  [Fluorescence diagnosis of porphyrin-marked urothelial tumors. Status of experimental development].

Authors:  D Jocham; R Baumgartner; N Fuchs; H Lenz; H Stepp; E Unsöld
Journal:  Urologe A       Date:  1989-03       Impact factor: 0.639

3.  Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study.

Authors:  Dieter Jocham; Fred Witjes; Sigrid Wagner; Bram Zeylemaker; Jeroen van Moorselaar; Marc-Oliver Grimm; Rolf Muschter; Gralf Popken; Frank König; Ruth Knüchel; Karl-Heinz Kurth
Journal:  J Urol       Date:  2005-09       Impact factor: 7.450

4.  Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study.

Authors:  Dmitry I Daniltchenko; Claus R Riedl; Markus D Sachs; Frank Koenig; Kurosch L Daha; Heinz Pflueger; Stefan A Loening; Dietmar Schnorr
Journal:  J Urol       Date:  2005-12       Impact factor: 7.450

Review 5.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update.

Authors:  Marko Babjuk; Willem Oosterlinck; Richard Sylvester; Eero Kaasinen; Andreas Böhle; Juan Palou-Redorta; Morgan Rouprêt
Journal:  Eur Urol       Date:  2011-03-22       Impact factor: 20.096

6.  Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer.

Authors:  Arnulf Stenzl; Maximilian Burger; Yves Fradet; Lance A Mynderse; Mark S Soloway; J Alfred Witjes; Martin Kriegmair; Alexander Karl; Yu Shen; H Barton Grossman
Journal:  J Urol       Date:  2010-09-17       Impact factor: 7.450

7.  Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer--a multicenter study.

Authors:  Patrice Jichlinski; Louis Guillou; Steinar J Karlsen; Per-Uno Malmström; Dieter Jocham; Bjørn Brennhovd; Eva Johansson; Thomas Gärtner; Norbert Lange; Hubert van den Bergh; Hans-Jürg Leisinger
Journal:  J Urol       Date:  2003-07       Impact factor: 7.450

8.  A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study.

Authors:  Yves Fradet; H Barton Grossman; Leonard Gomella; Seth Lerner; Michael Cookson; David Albala; Michael J Droller
Journal:  J Urol       Date:  2007-05-11       Impact factor: 7.450

9.  Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study.

Authors:  Stefan Denzinger; Maximilian Burger; Bernhard Walter; Ruth Knuechel; Wolfgang Roessler; Wolf F Wieland; Thomas Filbeck
Journal:  Urology       Date:  2007-04       Impact factor: 2.649

10.  Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy.

Authors:  H Barton Grossman; Arnulf Stenzl; Yves Fradet; Lance A Mynderse; Martin Kriegmair; J Alfred Witjes; Mark S Soloway; Alexander Karl; Maximilian Burger
Journal:  J Urol       Date:  2012-05-12       Impact factor: 7.450

View more
  3 in total

1.  Colorful lighting in the operating room.

Authors:  Ching-Hsuan Tung
Journal:  Quant Imaging Med Surg       Date:  2013-08

2.  'Real-life experience': recurrence rate at 3 years with Hexvix® photodynamic diagnosis-assisted TURBT compared with good quality white light TURBT in new NMIBC-a prospective controlled study.

Authors:  Kevin M Gallagher; Kayleigh Gray; Claire H Anderson; Hannah Lee; Sarah Stewart; Roland Donat; Paramananthan Mariappan
Journal:  World J Urol       Date:  2017-08-12       Impact factor: 4.226

Review 3.  Explainable artificial intelligence (XAI): closing the gap between image analysis and navigation in complex invasive diagnostic procedures.

Authors:  S O'Sullivan; M Janssen; Andreas Holzinger; Nathalie Nevejans; O Eminaga; C P Meyer; Arkadiusz Miernik
Journal:  World J Urol       Date:  2022-01-27       Impact factor: 3.661

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.